MorphoSys AG may not have added much more detail about its closely-watched myelofibrosis candidate pelabresib at the American Society of Hematology meeting but as the doors closed at the San Diego congress, the consensus was that the German biotech is well placed to get approval for one of the sector’s most valuable late-stage assets.
MorphoSys May Be One To Watch at J.P. Morgan
Excitement continues to grow around pelabresib after the presentation of promising data for the German group’s myelofibrosis drug.
More from Financing
• By
CEO Kris Elverum told Scrip about the start-up’s platform for editing RNA to correct genetic variants that cause harm and to reproduce healthy variants as a means of treating disease.
• By
The four-year-old firm said it plans to advance programs toward the clinic from the funding round, which comes just over a year after signing two major pharma partnerships.
• By
Private Company Edition: The latest group of drug developers to announce venture capital financings is remarkable for its geographic diversity, from Character Biosciences’ $93m series B round in the US to Augustine’s $85m series B in Belgium to a $29.2m series C for Aculys in Japan.
• By
Kyoto-based venture moves HQ to California to expand R&D and business outreach for its regulatory T-cell technology, as it raises around $46m in public and private funding.